Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab
Scholar Rock (NASDAQ:SRRK) said the FDA’s prior complete response letter for its SMA drug apitegromab was linked to good manufacturing practice issues at Catalent Indiana’s fill-finish site, not clinical data. The company resubmitted its BLA on Mar. 30, 2026, with two manufacturing paths, and FDA is reviewing an agreed data package. It also discussed Phase III and a new Phase II FSHD study.
How this was made
The 30-second read
Why it matters
The key new trading input is the FDA’s current review status of a resubmitted BLA that offers an alternate manufacturing qualification path after the Catalent Indiana site was classified OAI.
Market read
Traders can frame the Sept. 30 FDA decision as a manufacturing-acceptance binary, with the alternate facility plan as the primary mitigation to prior OAI risk.
What to watch
The article notes commercial vials are held by a third party pending approval, labeling, and packaging, implying operational constraints that could extend timelines if the FDA delays.
Background
Scholar Rock previously received a complete response letter tied to GMP observations at Catalent Indiana’s fill-finish site, not to apitegromab’s clinical data.
Ticker impact
Scholar Rock says its apitegromab BLA was resubmitted March 30, 2026, with FDA reviewing a second fill-finish facility plan ahead of a Sept. 30 decision.
Elevated volatility into the Sept. 30 FDA decision, with upside if the alternate facility review proceeds smoothly and downside if manufacturing risk re-emerges.
The article discloses a concrete regulatory manufacturing update: OAI at Catalent Indiana, resubmission with two approval paths, and an FDA review of an agreed data package for the alternate facility.
Market effects
Highlights how CMC/manufacturing inspection outcomes can drive approval timing for SMA biologics, potentially affecting sentiment across neuromuscular biotech.
Europe angle is secondary, but EMA process discussions could influence broader European biotech regulatory expectations.
FDA manufacturing decisions can set read-across expectations for other protein therapeutics relying on fill-finish sites.
Counterpoint
Even with an alternate facility plan, the FDA could still require additional inspection or data, keeping approval risk elevated despite the company’s confidence.
Key entities
- companyScholar Rock
Clinical-stage biotech developing apitegromab for SMA; subject of the FDA decision timing and manufacturing-path update.
- drugapitegromab
Lead SMA program whose BLA approval depends on manufacturing site qualification after prior GMP observations.
- manufacturing_siteCatalent Indiana fill-finish site
Classified OAI; can continue commercial filling/release but cannot support new approvals using that facility.
- manufacturing_siteAlternate fill-finish facility
Has recent positive FDA and EMA inspection history; company expects qualification without a new inspection, though not ruled out.
